Aspira Women's Health Files 8-K

Ticker: AWHL · Form: 8-K · Filed: Oct 24, 2024 · CIK: 926617

Aspira Women'S Health INC. 8-K Filing Summary
FieldDetail
CompanyAspira Women'S Health INC. (AWHL)
Form Type8-K
Filed DateOct 24, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001, $10 million
Sentimentneutral

Sentiment: neutral

Topics: financial-statements, exhibits, sec-filing

TL;DR

Aspira Women's Health filed an 8-K for financial statements/exhibits. No major news.

AI Summary

On October 24, 2024, Aspira Women's Health Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update or disclosure related to the company's financial status. No specific material events or transactions were detailed in the provided excerpt.

Why It Matters

This filing serves as a public record of Aspira Women's Health Inc.'s financial disclosures, providing transparency to investors and stakeholders.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, not indicating any immediate material changes or risks.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report financial statements and exhibits.

What is the exact name of the company filing this report?

The exact name of the company is Aspira Women's Health Inc.

On what date was the earliest event reported in this filing?

The earliest event reported in this filing was on October 24, 2024.

In which U.S. state was Aspira Women's Health Inc. incorporated?

Aspira Women's Health Inc. was incorporated in Delaware.

What were some of the former names of Aspira Women's Health Inc.?

Some of the former names of Aspira Women's Health Inc. include VERMILLION, INC., CIPHERGEN BIOSYSTEMS INC, and ABIOTIC SYSTEMS.

Filing Stats: 459 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-10-24 08:00:33

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aspira Women's Health Inc. Date: October 24, 2024 By: /s/ Nicole Sandford Nicole Sandford, Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing